ScholarIQanswers from OpenAlex & ORCID
Michael J. Overman
ResearcherPublications, citations & collaboration network
Michael J. Overman is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michael J. Overman have?
ScholarIQindexed works
Michael J. Overman has 1,074 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michael J. Overman have?
ScholarIQcitation count
Michael J. Overman has 32,299 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michael J. Overman?
ScholarIQh-index
Michael J. Overman has an h-index of 80 in OpenAlex.
What is the i10-index of Michael J. Overman?
ScholarIQi10-index
Michael J. Overman has an i10-index of 300 in OpenAlex.
What is the ORCID of Michael J. Overman?
ScholarIQorcid
The ORCID for Michael J. Overman is on the source record.
What is the OpenAlex record for Michael J. Overman?
ScholarIQopenalex
The OpenAlex for Michael J. Overman is on the source record.
What are the most-cited papers on Michael J. Overman?
ScholarIQmost cited works
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman, Ray McDermott, Joseph L. Leach, Sara Lonardi, Heinz‐Josef Lenz, Michael A. Morse, Jayesh Desai, Andrew Hill, Michael D. Axelson, Rebecca A. Moss, Monica V. Goldberg, Z. Alexander Cao, Jean-Marie Ledeine, Gregory A. Maglinte, Scott Kopetz, Thierry André
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz‐Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Magali Svrcek, Rebecca A. Moss, Jean-Marie Ledeine, Z. Alexander Cao, Shital Kamble, Scott Kopetz, Thierry André
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi‐Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Linda M. Farkas, Ignacio Garrido‐Laguna, Jean L. Grem, Andrew J. Gunn, J. Randolph Hecht, Sarah E. Hoffe, Joleen M. Hubbard, Steven R. Hunt, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey A. Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna R. Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky‐Himelfarb, Christopher G. Willett, Kristina M. Gregory, Lisa A. Gurski
Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
Scott Kopetz, George J. Chang, Michael J. Overman, Cathy Eng, Daniel J. Sargent, David W. Larson, Axel Grothey, Jean‐Nicolas Vauthey, David M. Nagorney, Robert R. McWilliams
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Nilofer Azad, Yi‐Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Ignacio Garrido‐Laguna, Jean L. Grem, Andrew J. Gunn, J. Randolph Hecht, Sarah E. Hoffe, Joleen M. Hubbard, Steven R. Hunt, William R. Jeck, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Jennifer K. Maratt, Wells A. Messersmith, Jeffrey A. Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Eden Stotsky‐Himelfarb, Anna Tavakkoli, Christopher G. Willett, Kristina M. Gregory, Lisa A. Gurski